Neurofeedback News
What Is Neurofeedback? -
Whenever I mention that neurofeedback helped me regain my life after my multiple brain injuries — or that I’m now a neurofeedback provider — the first reaction is to ask me, what is neurofeedback? I’m ...
Rewiring Your Brain: Neurofeedback Goes Mainstream -
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Will Strahl walked up to my door with a massive black briefcase in his ...
What Is Neurofeedback Therapy And How Does It Work? -
Ashwini Nadkarni, M.D., is a board-certified psychiatrist, Assistant Professor at Harvard Medical School and Interim Vice Chair for Faculty Affairs in the Department of Psychiatry at Brigham and Women ...
Neurofeedback for ADHD: Significant, Lasting Improvement -
Computer-based neurofeedback can produce significant and lasting improvement in attention and focus in children with attention-deficit/hyperactivity disorder (ADHD ...
Neurofeedback Gains Popularity and Lab Attention -
You sit in a chair, facing a computer screen, while a clinician sticks electrodes to your scalp with a viscous goop that takes days to wash out of your hair. Wires from the sensors connect to a ...
Medical News Today
PubMed
Cost of waiting: association of EEG delay and poor functional outcome in adult status epilepticus -
CONCLUSION: In this cohort, prolonged waiting times for EEG for the diagnosis of SE were associated with worse neurological outcomes at discharge and higher mortality. Improving timely EEG access, including weekends, may be a modifiable system-level target to improve SE outcomes.
Intracranial mapping identifies high-frequency cortical dynamics underlying visual discomfort -
High-contrast striped patterns near 3 cycles per degree are well established as a cause of visual discomfort and perceptual distortions, which in clinical populations can manifest as symptoms such as migraines or seizures. This sensitivity has been linked to cortical hyperexcitability, characterized by abnormally increased neural responses to visual input. Although gamma-band oscillations in vi...
Closed-loop versus open-loop vagus nerve stimulation in drug-resistant epilepsy: Real-world comparative effectiveness across eras and exploratory analyses of age at seizure onset -
CONCLUSIONS: In an Asian cohort, closed-loop VNS seems to be associated with greater seizure reduction than open-loop VNS in this real-world cohort; however, because device type was perfectly aligned with implantation era, findings should be interpreted as comparative effectiveness across eras rather than definitive causal superiority. Age at seizure onset shows an exploratory association with ...
Parent-Reported Improvement in Seizure Control and Development After Phenylbutyrate Treatment in Children With STXBP1 and SLC6A1 -
CONCLUSIONS: Phenylbutyrate was generally well tolerated with improved seizure control and development in children with STXBP1- and SLC6A1-encephalopathy, although we observed 1 intensive care unit-level hospitalization from dose-related toxicity. These results support the use of phenylbutyrate treatment for DEEs and highlight safety considerations.
Predicting the efficacy of classic ketogenic diet therapy in children with refractory epilepsy using dynamic changes in the glucose-ketone index (GKI) -
CONCLUSION: A GKI > 9.63 on the first day of CKD therapy may serve as an early-warning indicator of poor treatment response. The early treatment phase-from the second day of halving carbohydrate intake to the first day of CKD-represents a critical window for metabolic transition. Monitoring dynamic changes in GKI and blood ketone may facilitate timely adjustment of intervention strategies.
A prospective natural history study protocol for clinical trial readiness in synaptic disorders -
OBJECTIVE: STXBP1-related disorder (STXBP1-RD) and SYNGAP1-related disorder (SYNGAP1-RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems. Both STXBP1-RD and SYNGAP1-RD are potential targets for disease-modifying therapies, but there is limited information in the literature describing the n...
Science Daily